30 March 2022
Global Health 50/50 has just launched its fifth annual report, Boards for All? A review of power, policy and people on the boards of organisations active in global health. The report this year has two main areas of focus: an in-depth analysis of the attributes of board members across 147 organisations, alongside the annual analysis of the individual performance of 200 organisations across our standard nine core variables on gender-related policies and practices.
MPP is very proud to have been listed as a very high performer by Global Health 50/50 through their 2022 assessment of publicly available gender-related policies, practices, and outcomes in 200 leading organisations active in global health. This places our organisation in the top 10% of the sample. In assessing the scores of MPP from 2020-2022, we have also been found to be a “consistently high scorer”.
Nonetheless, after analysing over 2,000 board seats across 146 leading global organisations active in the global health sector, Global Health 50/50 found that gender and geographic diversity are severely lacking in the boards of major organisations active in global health. Indeed, the study confirms that people from high-income countries dominate leadership positions, with only 25% of board seats held by nationals of all low- and middle-income countries, despite the fact that these countries are home to 84% of the world’s population. Alarmingly, the study reveals that women from low-income countries are excluded from decision-making processes, occupying only 17 (1%) of the more than 2,000 board seats assessed.
Access the report
Access MPP’s results
A launch event will take place on 1 April 2022 at 1:30 pm BST > more information can be found here.
Related Publications
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.